{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Instances of progressive disease","groups":[{"description":"Benign head and neck tumors will be treated with SBRT\n\nstereotactic body radiotherapy: 14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)","id":"OG000","title":"Benign Tumors"},{"description":"Malignant Head and Neck Tumors will be treated with SBRT.\n\nStereotactic body radiotherapy: 8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)","id":"OG001","title":"Malignant Tumors"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"12 patients did not have local recurrence rate data reported. 3 patients were enrolled but never treated. 6 patients were lost to follow up. 3 patients died before data was collected.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Local Recurrence","type":"PRIMARY","unitOfMeasure":"Participants"}